Leaflet: Information for the user
Lidocaína Kabi 20 mg/ml injectable solutionEFG
Lidocaine hydrochloride (as monohydrate)
Read this leaflet carefully before you start using this medicine, because it contains important information for you.
Lidocaína Kabi is a local anesthetic. It is used for:
No use Lidocaína Kabi:
-if you are allergic to hydrochloride lidocaine, to other similar anesthetic amides or to any of the other components of this medication (listed in section 6).
-if your blood volume is decreased (hypovolemia).
-if you have certain heart problems (irregular or slow heart rhythm).
Warnings and precautions
Consult your doctor, pharmacist or nurse before starting to use Lidocaína Kabi:
Children
Lidocaína Kabi is not recommended for use in neonates (less than one month old).
Use of Lidocaína Kabi with other medications
Inform your doctor or pharmacist if you are using, have used recently or may need to use any other medication.
Particularly, inform your doctor if you are taking any of the following medications, as they may interact with Lidocaína Kabi:
If adrenaline (epinephrine) is to be added to your lidocaine injection, you must also inform your doctor if you have high blood pressure, lack of blood supply to the brain, hyperactive thyroid gland or if you are taking antidepressant medications. If you are to receive a strong anesthetic to sedate you, you must inform your doctor if you have already received a lidocaine injection containing adrenaline (epinephrine).
If you are already taking one of these medications, speak with your doctor before using Lidocaína Kabi.
Pregnancy and lactation
If you are pregnant or breastfeeding, or if you think you may be pregnant or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Your doctor will only administer this medication during your pregnancy or during breastfeeding if they consider it necessary.
Driving and operating machines
Depending on where and how this medication is used, it may affect your ability to drive or operate machines. Your doctor will advise you if you can drive or use machines.
You should not drive or operate machines while under the effects of Lidocaína Kabi.
Lidocaína Kabi 20 mg/ml injectable solution contains sodium
This medication contains 32 mg (approximately 1.39 mmol) of sodium (main component of table salt) in each dose. This is equivalent to 1.6% of the maximum daily dietary intake of 2 mg of sodium recommended by the WHO for an adult.
Your doctor will decide on the most suitable dose for you based on your age and physical condition, as well as the site of injection, method used, and your response to the injection.
If you are given more Lidocaína Kabi than you should
Since this medication will be administered by a trained professional, it is unlikely that you will be given too much Lidocaína Kabi.
However, if you think you have received too much, or if you start to experience dizziness or drowsiness, numbness or tingling in the lips and around the mouth or buzzing in the ears, you should immediately inform the person administering the injection.
If you have any other questions about the use of this medication, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Inform your doctor or nurse immediately if you experience an allergic reaction, which includes::
Other possible side effects are:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
-Paresthesia (tingling, numbness)
-Dizziness
-Slow heart rate
-Increased blood pressure
-Vomiting (being sick)
Uncommon(may affect up to 1 in 100 people)
-Seizures
-Drowsiness, dizziness, loss of consciousness, tremors, tongue numbness, difficulty speaking (sometimes, these symptoms may indicate that too much lidocaine has been administered)
Rare(may affect up to 1 in 1000 people)
Unknown(cannot be estimated from available data)
After a spinal injection of Lidocaína Kabi, inform your doctor if you experience any of the following symptoms:
For patients who return home before the numbness or loss of sensation caused by a local anesthetic has worn off:
During the time you feel numbness in the injected area, serious injuries may occur without your knowledge. To avoid injuries, be extra careful until the anesthesia wears off or sensation and touch return.
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Human Medicines Pharmacovigilance System www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
This medication does not require special conditions for conservation.
After opening the ampule, use immediately and discard the unused portion of the solution.
Do not use if the ampule is damaged or broken.
If diluted in a 9 mg/ml (0.9%) sodium chloride solution or a 50 mg/ml (5%) glucose solution in strict aseptic conditions, the solution should also be used immediately.
However, if the diluted solution is not used immediately, it should not be conserved for more than 12 hours in strict aseptic conditions below 25°C.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. This will help protect the environment.
Composition of Lidocaína Kabi
Lidocaína Kabi 20 mg/ml injectable solution:
Each ml of injectable solution contains 20 mg ofhydrochloride of lidocaína (as monohidrato)corresponding to 16.22 mg of lidocaína.
Each 5 ml of injectable solution contains 100 mg ofhydrochloride of lidocaína.
Each 10 ml of injectable solution contains 200 mg ofhydrochloride of lidocaína.
Each 20 ml of injectable solution contains 400 mg ofhydrochloride of lidocaína.
Appearance of Lidocaína Kabi and contents of the package
Lidocaína Kabi is a transparent and colorless aqueous solution, practically free of visible particles.
Lidocaína Kabiis available inampoules of low-density polyethylene with a flip-off cap system (“twist-off”).
Package sizes
Ampoules of 5 ml in packs of 5, 10, 20, 50 or 100.
Ampoules of 10 ml in packs of 5, 10, 20, 50 or 100.
Ampoules of 20 ml in packs of 5, 10, 20, 50 or 100.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer responsible:
Marketing authorization holder
Fresenius Kabi España, S.A.U.
C/Marina 16-18
08005 Barcelona
Spain
Manufacturer responsible
Labesfal – Laboratórios Almiro, S.A.
Zona Industrial do Lagedo
3465-157 - Santiago de Besteiros
Portugal
This medicinal product is authorized in the member states of the European Economic Area under the following names:
Country member | Medicinal product name |
Belgium | Lidocaine Fresenius Kabi 10 mg/ml, 20 mg/ml solution for injection |
France | Lidocaïne Kabi 10 mg/ml, 20 mg/ml solution injectable |
Italy | Lidocaina Kabi |
Ireland | Lidocaine Hydrochloride 1%, 2% w/v solution for injection |
Poland | Lidocaine 1%, 2% Fresenius Kabi |
Portugal | Lidocaína Fresenius Kabi |
Romania | Lidocaina Fresenius Kabi 10mg/ml, 20mg/ml injectable solution |
Slovenia | Lidokain Kabi 10 mg/ml, 20 mg/ml solution for injection |
Spain | Lidocaína Kabi 10 mg/ml, 20 mg/ml injectable solution |
United Kingdom | Lidocaine Hydrochloride 1%, 2% w/v solution for injection |
This leaflet was last revised in:May 2018.
<------------------------------------------------------------------------------------------------------------------------>
This information is intended solely for medical professionals or healthcare professionals:
Special precautions
Lidocaína Kabi injectable solution is not recommended for use in neonates. In this age group, the optimal serum concentration of lidocaína required to avoid toxicity, such as convulsions and cardiac arrhythmias, is unknown.
Handling and compatibility
Lidocaína Kabi injectable solution may be diluted in sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solutions.
The diluted solution must be visually inspected and not used if it presents opalescence, visible particles or precipitates.
If diluted in sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solutions under strict aseptic conditions, the solution must also be used within 12 hours.
Lidocaína is incompatible with solutions containing amphotericin B, sodium sulfadiazine, methohexital sodium, cefazolin sodium, phenytoin, glyceryl trinitrate and other alkaline solutions. Therefore, it is not advisable to mix Lidocaína Kabi with other agents.
Stable drugs in acidic medium such as hydrochloride of adrenaline, noradrenaline tartrate or isoprenaline pmay deteriorate after being mixed with lidocaína hydrochloride and lidocaína solutions may elevate the pH above the maximum pH for their stability.
Residual waste disposal
All unused product or waste material must be disposed of in accordance with local requirements.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.